The effect of exenatide re-exposure on safety and efficacy

Peptides

Volumn 30, Issue 9, 2009, Pages 1771-1774

  Faludi, Peter ^a   Brodows, Robert ^b   Burger, Jude ^b   Ivanyi, Tibor ^b   Braun, Daniel K ^b  

^a UZSOKI HOSPITAL   (Hungary)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIBODY; BIGUANIDE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG REEXPOSURE; DRUG SAFETY; EVENING DOSAGE; EYE ALLERGY; FEMALE; GLYCEMIC CONTROL; HEADACHE; HUMAN; INFLUENZA; INJECTION SITE PRURITUS; INJECTION SITE RASH; LARYNX PAIN; LIVER CANCER; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SINUSITIS; SORE THROAT; THORAX PAIN; TOOTH PAIN; TREATMENT RESPONSE; VIRUS INFECTION;

AGED; ANTIBODIES; DIABETES MELLITUS, TYPE 2; DRUG HYPERSENSITIVITY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; VENOMS;

HELODERMA SUSPECTUM;

EID: 67849124134     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.06.026     Document Type: Article

References (12)

1. ® (exenatide) injection, Prescribing information. http://www.byetta.com, 2009.
2. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 29 (2007) 2333-2348
3. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
4. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
5. Di M.U., Arduini P., Tiberti C., Lombardi G., Pietravalle P., and Andreani D. Immunogenicity of biosynthetic human insulin. Humoral immune response in diabetic patients beginning insulin treatment and in patients previously treated with other insulins. Diabetes Res Clin Pract 2 (1986) 317-324
6. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267 (1992) 7402-7405
7. Gao Y., Yoon K.H., Chuang L.M., Mohan V., Ning G., Shah S., et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 83 (2009) 69-76
8. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
9. Marcos C., Cuesta J., Cuevas M., Balsa J., Fraj J., and Alvarez-Cuesta E. Specific IgE antibody response to human insulin in diabetic subjects. Allergol Immunopathol (Madr) 21 (1993) 141-144
10. Schnabel C.A., Fineberg S.E., and Kim D.D. Immunogenicity of xenopeptide hormone therapies. Peptides 27 (2006) 1902-1910
11. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 284 (2000) 3043-3045
12. Zinman B., Hoogwerf B.J., Duran G.S., Milton D.R., Giaconia J.M., Kim D.D., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146 (2007) 477-485